Dose Adjusted-EPOCH-R and Mediastinal Disease May Improve Outcomes for Patients with Gray-zone Lymphoma

Overview

Journal Br J Haematol

Specialty Hematology

Date 2016 Jul 6

PMID 27378601

Citations 4

Authors

Dai Chihara

Jason R Westin

Roberto N Miranda

Chan Y Cheah

Yasuhiro Oki

Francesco Turturro

Jorge E Romaguera

Sattva S Neelapu

Lorreta J Nastoupil

Luis E Fayad

M Alma Rodriguez

Nathan H Fowler

Robert Z Orlowski

Michael Wang

Fredrick B Hagemeister

L Jeffrey Medeiros

Michelle A Fanale

Affiliations

Soon will be listed here.

Citing Articles

Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report.

Hojo N, Nagasaki M, Mihara Y World J Clin Cases. 2022; 10(17):5708-5716.

PMID: 35979119 PMC: 9258378. DOI: 10.12998/wjcc.v10.i17.5708.

Unraveling the Mystery of Gray Zone Lymphoma in Human Immunodeficiency Virus-Seropositive Patients: Two Cases.

Ahluwalia A, Bondili L, Salamera J, Cholankeril M J Hematol. 2020; 9(4):132-136.

PMID: 33224393 PMC: 7665863. DOI: 10.14740/jh554.

"Do Not Ignore Musculoskeletal Pain"-Initial Presentation of a Rare Malignant Disease: Case Report and Literature Review.

Patel I, Akoluk A, Upadhyaya V, Makadia S, Douedi S, Farooq T J Investig Med High Impact Case Rep. 2020; 8:2324709620941316.

PMID: 32660277 PMC: 7361477. DOI: 10.1177/2324709620941316.

A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy.

Mallipudi R, Alquran L, Shenoy V, Leslie L, Conti J Case Rep Oncol Med. 2019; 2019:4121234.

PMID: 31110830 PMC: 6487142. DOI: 10.1155/2019/4121234.

References

Evens A, Kanakry J, Sehn L, Kritharis A, Feldman T, Kroll A . Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol. 2015; 90(9):778-83. DOI: 10.1002/ajh.24082. View

Dunleavy K, Pittaluga S, Maeda L, Advani R, Chen C, Hessler J . Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013; 368(15):1408-16. PMC: 4568999. DOI: 10.1056/NEJMoa1214561. View

Wilson W, Pittaluga S, Nicolae A, Camphausen K, Shovlin M, Steinberg S . A prospective study of mediastinal gray-zone lymphoma. Blood. 2014; 124(10):1563-9. PMC: 4155269. DOI: 10.1182/blood-2014-03-564906. View

Traverse-Glehen A, Pittaluga S, Gaulard P, Sorbara L, Alonso M, Raffeld M . Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005; 29(11):1411-21. DOI: 10.1097/01.pas.0000180856.74572.73. View

Romaguera J, Fayad L, Rodriguez M, Broglio K, Hagemeister F, Pro B . High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005; 23(28):7013-23. DOI: 10.1200/JCO.2005.01.1825. View